Metronidazole Βιοσερ (Metronidazole)

The drug is taken up by anaerobic microorganisms and reduced to reactive nitro radicals. These radicals bind to DNA, causing strand breakage and blocking nucleic acid synthesis, which leads to cell death of susceptible bacteria and protozoa while sparing aerobic cells.

The specific dose and duration are determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and other clinical factors. Healthcare professionals should follow local guidelines and individual patient needs.

Metronidazole is classified as Pregnancy Category B, indicating no evidence of risk in animal studies but limited human data. It may be used during pregnancy only if the potential benefit justifies the risk. Caution is advised during breastfeeding; consult a healthcare provider.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and import documentation.

Metronidazole is uniquely effective against obligate anaerobes and certain protozoa, offering a broad spectrum for anaerobic infections. Alternatives such as clindamycin or beta‑lactam/beta‑lactamase inhibitor combinations may be used, but metronidazole often provides superior activity against anaerobic Gram‑negative rods and protozoal pathogens.

Store at ambient temperature: keep the vial in its original packaging, protect from moisture and direct light, and avoid freezing. Ensure the container is tightly sealed when not in use to maintain product stability.

Metronidazole Βιοσερ is given by intravenous infusion under the supervision of a qualified healthcare professional. The infusion rate and dilution are determined by the prescriber and nursing staff according to the specific clinical protocol.

Serious risks include seizures, peripheral neuropathy, severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, hepatic toxicity, and neutropenia. Patients should be monitored for neurological symptoms, skin changes, liver function abnormalities, and blood count alterations during treatment.

Metronidazole is contraindicated in patients with a known hypersensitivity to the drug or other nitroimidazoles. Caution is also required for individuals with severe hepatic impairment, those receiving disulfiram, and patients with a history of seizures or neuropathy unless benefits outweigh risks.